CLINICAL_TRIALS
trial_result
· 2016-02-12
Clinical Trial Update: Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors [Phase 3]
Summary
Result update from a Phase 3 trial of lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitors; the study has completed and results have…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2016-02-12